Correction to: Circulating blood levels of IL-6, IFN-γ, and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study

Sánchez-Zauco, Norma; Torres, Javier; Gómez, Alejandro; Camorlinga‐Ponce, Margarita; Muñoz-Pérez, Leopoldo; Herrera‐Goepfert, Roberto; Medrano-Guzmán, Rafael; Giono-Cerezo, Silvia; Maldonado‐Bernal, Carmen

doi:10.1186/s12885-017-3657-y

Cited by 14 publications

(13 citation statements)

References 1 publication

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The highest among these values was 43.5 pg/ml. [9][10][11][12][13][14][15][16][17] F I G U R E 2 Simplified flow chart showing the number of studies. The included studies were 140.…”

Section: Resultsmentioning

confidence: 99%

Defining IL‐6 levels in healthy individuals: A meta‐analysis

Said

Al-Reesi

Al-Shizawi

et al. 2020

Journal of Medical Virology

102

View full text Add to dashboard Cite

Background Interleukin‐6 (IL‐6) is produced by and impacts different cell types in human. IL‐6 is associated with different diseases and viral infections, including COVID‐19. To our knowledge, no normal values were reported for IL‐6 in the blood of healthy individuals. We have reviewed and performed a meta‐analysis on a total of 140 studies, including 12,421 values for IL‐6 in the blood of healthy adult donors. Among these studies, 83 did not report a mean value and the standard deviation. Therefore, for the statistical analysis, we used the values reported in 57 studies, which included 3166 values for IL‐6. Results The reported values for IL‐6 in the blood of healthy donors varied between 0 and 43.5 pg/ml. The pooled estimate of IL‐6 was 5.186 pg/ml (95% confidence interval [CI]: 4.631, 5.740). As the age increased by 1 year, IL‐6 values increased by 0.05 pg/ml (95% CI: 0.02, 0.09; p < .01). Though the heterogenicity, as determined by I2 statistics, was high in our study, the differences in IL‐6 values are still at the level of a few pg/ml, which might be related to the differences in the conditions that influence IL‐6 production in the healthy population. Conclusions This is the first meta‐analysis reporting the levels of IL‐6 in the blood of healthy donors based on a large number of studies and donors. Therefore the 95% CI values determined in our study could well serve as a reference range for quick decision‐making in clinical interventions, particularly those aiming to inhibit IL‐6, especially urgent interventions, for example, COVID‐19.

show abstract

“…The highest among these values was 43.5 pg/ml. [9][10][11][12][13][14][15][16][17] F I G U R E 2 Simplified flow chart showing the number of studies. The included studies were 140.…”

Section: Resultsmentioning

confidence: 99%

Defining IL‐6 levels in healthy individuals: A meta‐analysis

Said

Al-Reesi

Al-Shizawi

et al. 2020

Journal of Medical Virology

102

View full text Add to dashboard Cite

show abstract

“…In particular, we found an upregulation of several genes involved in proliferation and lipid metabolism such as HNF4A, functionally required for the development of gastric cancer regulating IDH1 ( 65 ), APOC1, recognized as new diagnostic and prognostic marker of gastric cancer ( 66 ), APOE, which is highly expressed in gastric cancers and correlates with progression and invasion ( 67 , 68 ), FASN, associated with diffuse gastric cancer and poor prognosis ( 69 ). Conversely, we found a downregulation of VLDLR, whose genetic or epigenetic silencing contributes to gastric carcinogenesis ( 70 ), CYP27A1, which induces T cell dysfunction, thus promoting breast cancer progression ( 71 ) and CCL2, downregulated in diffuse gastric cancer primarily in advanced stages ( 72 ).…”

Section: Resultsmentioning

confidence: 93%

“…Surprisingly, the analysis of diffuse gastric cancer subset revealed in addition to a modulation of immune and proliferation pathways, also an upregulation of genes involved in proliferation and lipid metabolism such as HNF4A ( 65 ), APOC1 ( 66 ),, APOE ( 67 , 68 ),, FASN ( 69 ), while the expression of VLDLR ( 70 ) and CCL2 ( 72 ), were downregulated.…”

Section: Discussionmentioning

confidence: 99%

Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential

et al. 2021

View full text Add to dashboard Cite

Gastric cancer is the fifth most common malignancy but the third leading cause of cancer-associated mortality worldwide. Therapy for gastric cancer remain largely suboptimal making the identification of novel therapeutic targets an urgent medical need. In the present study we have carried out a high-throughput sequencing of transcriptome expression in patients with gastric cancers. Twenty-four patients, among a series of 53, who underwent an attempt of curative surgery for gastric cancers in a single center, were enrolled. Patients were sub-grouped according to their histopathology into diffuse and intestinal types, and the transcriptome of the two subgroups assessed by RNAseq analysis and compared to the normal gastric mucosa. The results of this investigation demonstrated that the two histopathology phenotypes express two different patterns of gene expression. A total of 2,064 transcripts were differentially expressed between neoplastic and non-neoplastic tissues: 772 were specific for the intestinal type and 407 for the diffuse type. Only 885 transcripts were simultaneously differentially expressed by both tumors. The per pathway analysis demonstrated an enrichment of extracellular matrix and immune dysfunction in the intestinal type including CXCR2, CXCR1, FPR2, CARD14, EFNA2, AQ9, TRIP13, KLK11 and GHRL. At the univariate analysis reduced levels AQP9 was found to be a negative predictor of 4 years survival. In the diffuse type low levels CXCR2 and high levels of CARD14 mRNA were negative predictors of 4 years survival. In summary, we have identified a group of genes differentially regulated in the intestinal and diffuse histotypes of gastric cancers with AQP9, CARD14 and CXCR2 impacting on patients’ prognosis, although CXCR2 is the only factor independently impacting overall survival.

show abstract

“…In particular, we found an upregulation of several genes involved in proliferation and lipid metabolism such as HNF4A, functionally required for the development of gastric cancer regulating IDH1 [65], APOC1, recognized as new diagnostic and prognostic marker of gastric cancer [66], APOE, which is highly expressed in gastric cancers and correlates with progression and invasion [67,68], FASN, associated with diffuse gastric cancer and poor prognosis [69]. Conversely, we found a downregulation of VLDLR, whose genetic or epigenetic silencing contributes to gastric carcinogenesis [70], CYP27A1, which induces T cell dysfunction, thus promoting breast cancer progression [71] and CCL2, downregulated in diffuse gastric cancer primarily in advanced stages [72].…”

Section: Resultsmentioning

confidence: 99%

“…Surprisingly, the analysis of diffuse gastric cancer subset revealed in addition to a modulation of immune and proliferation pathways, also an upregulation of genes involved in proliferation and lipid metabolism such as HNF4A [65], APOC1, [66], APOE, [67,68], FASN [69], while the expression of VLDLR [70] and CCL2 [72], were downregulated.…”

Section: Discussionmentioning

confidence: 99%

Analysis of gastric cancer transcriptome allows the identification of histotype specific molecular signatures with prognostic potential

Carino

Graziosi

Marchianò

et al. 2021

Preprint

View full text Add to dashboard Cite

Gastric cancer is the fifth most common malignancy but the third leading cause of cancer-associated mortality worldwide. Therapy for gastric cancer remain largely suboptimal making the identification of novel therapeutic targets an urgent medical need. In the present study we have carried out a high-throughput sequencing of transcriptome expression in patients with gastric cancers. Twenty-four patients, among a series of 53, who underwent an attempt of curative surgery for gastric cancers in a single center, were enrolled. Patients were sub-grouped according to their histopathology into diffuse and intestinal types, and the transcriptome of the two subgroups assessed by RNAseq analysis and compared to the normal gastric mucosa. The results of this investigation demonstrated that the two histopathology phenotypes express two different patterns of gene expression. A total of 2064 transcripts were differentially expressed between neoplastic and non neoplastic tissues: 772 were specific for the intestinal type and 407 for the diffuse type. Only 885 transcripts were simultaneously differentially expressed by both tumors. The per pathway analysis demonstrated an enrichment of extracellular matrix and immune dysfunction in the intestinal type including CXCR2, CXCR1, FPR2, CARD14, EFNA2, AQ9, TRIP13, KLK11 and GHRL. At the univariate analysis reduced levels AQP9 was found to be a negative predictor of 4 years survival. In the diffuse type low levels CXCR2 and high levels of CARD14 mRNA were negative predictors of 4 years survival. In summary, we have identified a group of genes differentially regulated in the intestinal and diffuse histo-types of gastric cancers with AQP9, CARD14 and CXCR2 impacting on patients prognosis, although CXCR2 is the only factor independently impacting overall survival.

show abstract

Correction to: Circulating blood levels of IL-6, IFN-γ, and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study

Cited by 14 publications

References 1 publication

Defining IL‐6 levels in healthy individuals: A meta‐analysis

Defining IL‐6 levels in healthy individuals: A meta‐analysis

Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential

Analysis of gastric cancer transcriptome allows the identification of histotype specific molecular signatures with prognostic potential

Contact Info

Product

Resources

About